These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 29617082)
41. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level. Lin VC; Liao CH; Wang CC; Kuo HC J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231 [TBL] [Abstract][Full Text] [Related]
42. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Djavan B; Marberger M Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649 [TBL] [Abstract][Full Text] [Related]
43. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Novara G; Chapple CR; Montorsi F BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313 [TBL] [Abstract][Full Text] [Related]
44. [The role of alpha blockers in the treatment of lower urinary tract symptoms/benign prostatic hyperplasia: are all the same? Silodosin in "real life"]. Alcántara Montero A; Semergen; 2016 Jul; 42 Suppl 2():1-9. PubMed ID: 27889014 [TBL] [Abstract][Full Text] [Related]
45. Medical therapy for benign prostatic hyperplasia: a review of the literature. Clifford GM; Farmer RD Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436 [TBL] [Abstract][Full Text] [Related]
47. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Tatemichi S; Tomiyama Y; Maruyama I; Kobayashi S; Kobayashi K; Maezawa A; Kobayashi M; Yamazaki Y; Shibata N Neurourol Urodyn; 2006; 25(7):792-9; discussion 800-1. PubMed ID: 16894620 [TBL] [Abstract][Full Text] [Related]
48. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Schilit S; Benzeroual KE Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995 [TBL] [Abstract][Full Text] [Related]
49. Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia. Kobayashi S; Tomiyama Y; Tatemichi S; Hoyano Y; Kobayashi M; Yamazaki Y Eur J Pharmacol; 2009 Jun; 613(1-3):135-40. PubMed ID: 19389393 [TBL] [Abstract][Full Text] [Related]
50. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. Elterman DS; Lawrentschuk N; Guns E; Hersey K; Adomat H; Wood CA; Fleshner N J Urol; 2010 May; 183(5):2085-9. PubMed ID: 20303529 [TBL] [Abstract][Full Text] [Related]
51. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin. Ito H; Sano F; Ogawa T; Yao M Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900 [TBL] [Abstract][Full Text] [Related]
52. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia. Türkeri LN; Ozyürek M; Ersev D; Akdaş A Arch Esp Urol; 2001 Mar; 54(2):191-6. PubMed ID: 11341128 [TBL] [Abstract][Full Text] [Related]
53. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Benning CM; Kyprianou N Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715 [TBL] [Abstract][Full Text] [Related]
54. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145 [TBL] [Abstract][Full Text] [Related]
55. Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride. El-Tatawy H; Gameel T; El-enen MA; Hagras A; Mousa A; El-Bahnasy AH; Raheem AA; Abu-dewan K Arch Ital Urol Androl; 2015 Sep; 87(3):238-42. PubMed ID: 26428648 [TBL] [Abstract][Full Text] [Related]
56. Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. Buono R; Briganti A; Freschi M; Villa L; La Croce G; Moschini M; Benigni F; Castiglione F; Montorsi F; Hedlund P Eur J Pharmacol; 2014 Dec; 744():42-51. PubMed ID: 25261033 [TBL] [Abstract][Full Text] [Related]
57. [Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience]. Larosa M; Ferretti S; Salsi P; Simonazzi M Acta Biomed Ateneo Parmense; 1994; 65(1-2):23-8. PubMed ID: 7528458 [TBL] [Abstract][Full Text] [Related]
58. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810 [TBL] [Abstract][Full Text] [Related]
59. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. Kawabe K; Yoshida M; Homma Y; BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121 [TBL] [Abstract][Full Text] [Related]
60. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]